Go back to the e-newsletter >Ponant, the world’s only French-flag cruise line, has completed its acquisition by Artemis, holding company of the Pinault family.Jean-Emmanuel Sauvée, Co-founder and CEO of Ponant, said: “In the last three years, together we have launched and financed new ships, opened new offices in Australia and China, and acquired a leading player in the American cultural cruise market. Today we are entering a new phase with a long-term shareholder who, like Bridgepoint, shares our vision and ambitions for Ponant as a global player in the high-end cruise market.”Ponant will now work with Artemis to ramp-up its internationalisation programme, consolidate its positions in France, Switzerland and Belgium and thereby enter a new phase in its development.Under the current Executive Management team, led by Co-founder and CEO Jean-Emmanuel Sauvée and Véronique Saadé, Deputy CEO, Artemis intends to continue Ponant’s strategy focused on innovation.Go back to the e-newsletter >
It could trade for 400 times more than the price of crude oil and 2,000 times more than iron ore. If sold off the shelf, it could cost more than 150 times the price of a gallon of cow’s milk and 15 times more than coffee. Going for as much as $4 per ounce, human breast milk is a hot commodity that is emerging as a surprisingly cutthroat industry, one that states are now seeking to regulate amid a battle for control between nonprofit and for-profit banks that supply hospital neonatal units. … Each side claims the moral high ground, with nonprofits generally saying milk distribution should be altruistic and for-profit companies arguing mothers deserve to be compensated. (Catalini, 7/7) The Associated Press: The Battle For Control Of The Human Breast Milk Industry Nonprofit, For-Profit Groups Vie For Control Of Lucrative Breast Milk Market The nonprofit groups generally say milk distribution should be altruistic, while for-profit companies argue mothers deserve to be compensated, The Associated Press reports. Meanwhile, the Pittsburgh Post-Gazette examines why paying cash for prescription drugs may be cheaper than using your insurance card. Charles Conn stopped in to see his pharmacist to fill a prescription for a cough that had persisted for a month. Once he saw how much the medication cost, he could have used a side order of blood pressure pills. The price, under his insurance plan, was $91 for 30 nonnarcotic Benzonatate gel caps. … Luckily, the pharmacist … had flagged the prescription and was able to sell the medication for $26.10 in cash. Mr. Conn, 66, happily paid the lower price but the episode left him wondering: Why would a prescription cost nearly four times more through his insurance plan than paying cash? The answer may lie in the vagaries of pharmaceutical pricing, which include the wholesale prices that hardly anyone pays and the largely unseen influence of third-party pharmacy benefit managers. (Twedt, 7/6) The Pittsburgh Post-Gazette: When Paying Cash For A Prescription Is Cheaper Than Using Insurance This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.